Summit Therapeutics Inc. (SMMT )

Currency in USD Disclaimer
$33.18 -$0.05 (-0.15%)
Open 04/24/2025
$32.64
$33.55
$2.1
$33.89

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol SMMT
  • Company Summit Therapeutics Inc.
  • Price $33.18
  • Changes Percentage -0.15
  • Change -0.05
  • Day Low $32.64
  • Day High $33.55
  • Year High $33.89
  • Year Low $2.1
  • Market Cap $24,513,096,431
  • Price Avg 50 EMA (D) $20.36
  • Price Avg 200 EMA (D) $18.19
  • Exchange NASDAQ
  • Volume 11,768,375
  • Average Volume 2,937,176
  • Open $33
  • Previous Close $33.23
  • EPS -0.38
  • PE -87.45
  • Earnings Announcement 2025-04-29 12:30:00
  • Shares Outstanding $737,679,700

Company brief: SUMMIT THERAPEUTICS INC. (SMMT )

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

SMMT Corporation News

This Company's Co-CEOs Just Bought More Shares. Should You?

This Company's Co-CEOs Just Bought More Shares. Should You?

April 23, 2025 at 9:45 am ET

fool.com -- Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights ...

Income Statement